Erratum
Open Access
Erratum to: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study
Published: 03 March 2011
After publication of our recent article [1], we noticed an error in the unit for the area under the time-concentration curve between 0 and 12 hours (AUC0-12 h). Throughout the article and Table 1 the unit should be mg·h/L (mg multiplied by hour per L) not mg/hour/L.
Table 1
Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical outcome (univariate analysis)
Total | Successes | Failures | ||
|---|---|---|---|---|
Inclusion characteristic | n= 26 | n= 17 | n= 8 | Pvaluea |
Demographic | ||||
Females/Males, number | 16/10 | 12/5 | 4/4 | 0.28b |
Age, years | 46 (35-61)a | 46.5 (35-61) | 46 (38-61) | 0.9 |
Body weight, kg | 60 (56-75) | 60 (56-75) | 62 (58-82.5) | 0.62 |
Disease | ||||
Duration before entry, months | 11 (7-14) | 11 (7-12) | 10 (6-13) | 0.30 |
SLEDAI score | 0 (0-2) | 0 (0-2) | 0 (0-2) | 0.20 |
C3, g/L | 1 (0.6-1.1) | 1 (0.9-1.1) | 0.8 (0.56-0.96) | 0.21 |
C4, g/L | 0.2 (0.1-0.2) | 0.2 (0.1-0.2) | 0.2 (0.16-0.24) | 0.78 |
Anti-double-stranded DNA, IU/mL | 24 (6-51) | 8 (1-32) | 38 (9-55) | 0.19 |
Biological | ||||
GFR, mL/minute | 95 (67-125) | 95 (67-125) | 93.5 (76-109) | 0.64 |
Albumin, g/L | 40 (39.8-43.8) | 40 (37.9-43.8) | 42.8 (40-46.9) | 0.33 |
Aspartate aminotransferase, IU/L | 23 (19-26) | 23 (17.5-24.5) | 28 (20-33) | 0.26 |
Alanine aminotransferase, IU/L | 22 (15-29) | 19 (13-24.5) | 25 (19-37) | 0.21 |
γ-Glutamyltransferase, IU/L | 24 (17-63) | 23 (17-21) | 42 (17-61) | 0.92 |
Treatment | ||||
MMF, g/day | 2 (2-2) | 2 (2-2) | 2 (2-2) | 0.9 |
Corticosteroids, mg/day | 11 (7-35) | 10 (5-20) | 15 (7-45) | 0.37 |
Months of MMF therapy | 2 (1-3) | 2 (1-3) | 2 (1-3) | 0.56 |
Months of corticosteroids | 10 (6-13) | 10 (5-15) | 9 (5-14) | 0.12 |
MPA pharmacokinetic parameters | ||||
AUC0-12 h' mg·hour/L | 64.7 (38.2-82) | 73.1 (61.8-95) | 37.7 (32-43.7) | 0.003 |
Cmax' mg/L | 16.1 (9.5-18.5) | 16.3 (9.7-17.4) | 13.3 (7-22.5) | 0.69 |
Tmax' hours | 1 (1-2) | 1 (1-2) | 1.1 (1-2) | 0.82 |
C12 h' mg/L | 2.4 (1.5-4.1) | 3.7 (2.3-4.9) | 1.5 (0.6-2.1) | 0.008 |
MPAG pharmacokinetic parameters | ||||
AUC0-12 h' mg·hour/L | 775.3 (475-1,026) | 791 (635-1,166) | 678.8 (426-840.6) | 0.22 |
Tmax' hours | 2 (2-3) | 2.3 (2-3) | 1.3 (1-2) | 0.01 |
C12 h' mg/L | 32.1 (24.3-41.9) | 34.7 (26.4-49.2) | 29.8 (15.5-40) | 0.26 |
MPAG/MPA AUC0-12 h ratio | 11.5 (8.3-20.7) | 10.9 (6.2-14.8) | 18.7 (14.1-22.7) | 0.07 |
MPAG/MPA C12 h ratio | 11.5 (6.8-17.3) | 10.2 (6.3-15) | 18.7 (11.5-47.2) | 0.02 |
The correct table is given here as Table 1.
Notes
Declarations
Authors’ Affiliations
(1)
Laboratoire de Pharmacocinétique et Pharmacie Clinique EA2968, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan
(2)
Service de Médecine Interne et des Maladies Infectieuses, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan
References
- Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. Arthritis Res Ther. 2010, 12: R217-10.1186/ar3202.PubMed CentralView ArticlePubMedGoogle Scholar
Copyright
© BioMed Central Ltd 2011
